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The core site in the Moloney murine leukemia virus (Moloney MLV) enhancer was previously shown to be
an important determinant of the T-cell disease specificity of the virus. Mutation of the core site resulted in a
significant shift in disease specificity of the Moloney virus from T-cell leukemia to erythroleukemia. We and
others have since determined that a protein that binds the core site, one of the core-binding factors (CBF) is
highly expressed in thymus and is essential for hematopoiesis. Here we test the hypothesis that CBF plays a
critical role in mediating pathogenesis of Moloney MLV in vivo. We measured the affinity of CBF for most core
sites found in MLV enhancers, introduced sites with different affinities for CBF into the Moloney MLV genome,
and determined the effects of these sites on viral pathogenesis. We found a correlation between CBF affinity and
the latent period of disease onset, in that Moloney MLVs with high-affinity CBF binding sites induced leukemia
following a shorter latent period than viruses with lower-affinity sites. The T-cell disease specificity of Moloney
MLV also appeared to correlate with the affinity of CBF for its binding site. The data support a role for CBF
in determining the pathogenic properties of Moloney MLV.
Murine leukemia viruses (MLVs) are replication-competent
retroviruses, some of which induce leukemias and lymphomas
when injected into newborn mice. Both viral and host genetic
factors influence the leukemogenicity of MLVs and their dis-
ease specificities. One determinant of MLV pathogenesis is the
viral transcriptional enhancer. Enhancers can influence the
tissue tropism of an MLV, the rate of disease onset, and dis-
ease specificity. For example, the SL3-3 MLV, a thymotropic,
highly leukemogenic virus, has a potent transcriptional en-
hancer that significantly influences pathogenesis by this virus.
Replacement of the SL3-3 enhancer (U3 region) with that
from the weakly leukemogenic Akv virus converts SL3-3
MLV into an essentially nonpathogenic virus (36). Another
well-studied example is the enhancer from the Moloney
MLV, which determines the selectivity of the Moloney virus
for inducing T-cell lymphomas. Substitution of the Moloney
virus enhancer with that from the erythroleukemogenic
Friend MLV switches the disease specificity of Moloney
MLV from T-cell lymphoma to erythroleukemia (9, 10, 22,
31, 38).
An abundance of transcription factor binding sites have
been found in MLV enhancers, several of which influence
MLV pathogenesis. One site that has received considerable
attention is the so-called core site, which was shown to
contribute to the pathogenic properties of both the Moloney
and SL3-3 MLVs. Mutation of the core site in Moloney
MLV significantly altered the disease specificity of Moloney
MLV from T-cell lymphoma to erythroleukemia (70). In
SL3-3 MLV, core site mutations had different effects, de-
pending upon the particular base pair change that was in-
troduced and the number of core sites mutated. Some mu-
tations increased the latent period of disease onset by SL3-3,
while others almost completely attenuated pathogenesis by
the virus (1, 27, 47). SL3-3 MLV enhancers containing core
site mutations often accumulated secondary mutations in
vivo that restored some amount of transcriptional activity to
the enhancer and pathogenic potential to the virus (17, 18,
47).
We and others identified and purified a protein that binds
the SL3-3 and Moloney MLV core sites and named it CBF
(for core-binding factor) (33, 40, 69, 78, 82). We purified
CBF from calf thymus based on its ability to bind the wild-
type Moloney MLV core site but not the mutated core site
that shifted disease specificity of Moloney MLV to erythro-
leukemia (70, 82). CBF was independently purified based on
its binding to the polyomavirus enhancer and is also known
as the polyomavirus enhancer binding protein 2 (PEBP2)
(33).
Numerous studies have underscored the importance of CBF
in hematopoiesis. CBF is a heterodimer consisting of a DNA-
binding subunit called CBFa and a non-DNA-binding subunit,
CBFb (33, 54, 55, 83). Three related genes encode CBFa
subunits (Cbfa1, Cbfa2, and Cbfa3), and one gene encodes the
common CBFb subunit (Cbfb) (2, 3, 37, 39, 46, 54, 55, 83).
Homozygous disruption of two of the CBF genes in mice,
Cbfa2 and Cbfb, blocks fetal liver hematopoiesis (48, 56, 64, 80,
81). All definitive hematopoietic lineages are affected by the
Cbfa2 and Cbfb mutations, suggesting that Cbfa2 and Cbfb
are required at the level of the pluripotent hematopoietic
stem cell. In addition, mutations in the human Cbfa2 and
Cbfb homologues (CBFA2 [also known as AML1] and
CBFB) are associated with leukemias in humans. The
CBFA2 gene is the target of the t(8;21)(q22;q22) associated
with 15% of de novo acute myeloid leukemias (5, 46), the
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t(12;21)(p13;q22) found in 30% of pediatric de novo acute
lymphocytic leukemias (24, 42, 61, 62, 66), and the relatively
rare t(3;21)(q26;q22) and t(16;21)(q24;q22) found in thera-
py-related leukemias and myelodysplasias (20, 52, 53). The
CBFB gene is disrupted in approximately 15% of acute
myeloid leukemias by inv(16)(p13;q22), t(16;16), and
del(16)(q22) (39, 67). CBF binds a number of cellular genes
transcribed in hematopoietic cells, including genes encoding
the T-cell receptor a, b, g, and d chains (TCRa, TCRb,
TCRg, and TCRd, respectively), immunoglobulin m chain,
interleukin 3, granulocyte/monocyte colony-stimulating fac-
tor, CD3ε, myeloperoxidase, neutrophil elastase, and gran-
zyme B serine protease (8, 16, 19, 21, 28, 30, 51, 59, 60, 76,
84, 87).
The importance of CBF in hematopoietic cells makes it a
strong candidate for the factor that contributes to the leuke-
mogenic properties of MLVs in vivo. However, CBF is not the
only transcription factor that binds the Moloney and SL3-3
MLV core sites in vitro. Activating protein 3 (AP-3), mamma-
lian C-type retrovirus enhancer factor 1 (MCREF-1), and SL3
core-binding factor (S-CBF) also bind MLV core sites (40, 41,
44, 75), and there may be other core-binding factors not yet
identified. To address the question of whether CBF is the
relevant core-binding factor for Moloney MLV pathogenesis in
vivo, we considered two approaches. One approach is to elim-
inate or overexpress CBF in mice and determine whether mod-
ification of CBF levels affects pathogenesis by Moloney MLV.
However, an inherent difficulty with this approach is that he-
matopoiesis itself may be severely perturbed by anomalous
levels of CBF. This is certainly the case when CBFa2 or CBFb
is eliminated entirely, which severely impairs hematopoiesis,
resulting in embryonic lethality (48, 56, 64, 80, 81). Overex-
pression is also likely to be problematic, as evidenced by the
recent discovery that Cbfa1 is a preferential proviral insertion
site in lymphomas induced by Moloney MLV in c-myc trans-
genic mice (72).
An alternative approach, and the tack we chose to follow, is
to systematically modify the affinity of CBF for the core site in
the Moloney MLV enhancer by altering the nucleotide com-
position of the site. Our hypothesis was that if CBF is the
relevant core-binding factor for Moloney MLV pathogenesis in
vivo, we should observe a correlation between the affinity of
CBF for its site and the latent period of disease onset, and/or
the disease specificity of the virus. To this end, we measured
the affinity of CBF for a large panel of naturally occurring and
synthetic core sites. We identified core sites whose affinities for
CBF span 5 orders of magnitude, engineered those sites into
the Moloney MLV genome, and examined their impact on
pathogenesis by Moloney MLV. We observed a relationship
between CBF affinity and the latent period of disease onset, in
that Moloney MLVs with high-affinity CBF binding sites in-
duced leukemia or lymphoma with a shorter latent period than
viruses with low-affinity sites. Disease specificity also correlated
with the affinity of CBF for its site, supporting a role for CBF
in Moloney MLV pathogenesis.
MATERIALS AND METHODS
Expression and purification of the CBFa2 Runt domain. A DNA fragment
encoding the DNA-binding (Runt) domain from the murine CBFa2 protein
(amino acids 41 to 190) (3) was amplified by PCR using the following primers:
59-CGGAATTCCCATATGGCCAGCAAGCTGAGGAGC-39 (sense) and 59-C
GGGATCCTTACTCGTGCTGGTTCTTCCCGGGCTTGGTCTGATC-39
(antisense). The antisense primer introduces a translational stop codon followed
by codons for the amino acids KNQHE immediately 39 to codon 190 of CBFa2.
PCR products were digested with NdeI and BamHI, subcloned into the corre-
sponding sites of the pET-3c vector (Novagen, Madison, Wis.), and transformed
into the Escherichia coli BL21(DE3)LysS for expression (74). A single colony was
grown to an absorbance (A600) of 0.3 to 0.4 in Luria-Bertani (LB) medium
containing 100 mg of carbenicillin per ml and 50 mg of chloramphenicol per ml,
and a glycerol stock was prepared.
All purification steps were performed at 4°C, unless otherwise noted. A scrap-
ing of the frozen bacterial stock was thawed at room temperature, and 1 ml was
diluted into 1.0 ml of LB medium. A 1-ml aliquot of this 1:1,000 dilution was used
to inoculate 1 liter of LB medium containing 100 mg of carbenicillin per ml and
50 mg of chloramphenicol per ml. The cells were grown for approximately 16 h
at 37°C to an absorbance (A600) of 0.3 to 0.4, and expression was induced with 1
mM isopropyl-b-D-thiogalactopyranoside (IPTG). Cells were harvested between
1 and 3 h postinduction by centrifugation at 4,800 3 g. The bacterial pellet was
resuspended in an equal weight of lysis buffer (10% sucrose, 50 mM Tris-HCl
[pH 7.5], protease inhibitors [1 mM Pefabloc, 1 mM phenylmethylsulfonyl fluo-
ride, 50 mM Calpain inhibitor 1, 1 mg of leupeptin per ml, 1 mg of pepstatin A per
ml, 2 mg of aprotinin per ml] [Sigma]). The cells were dropped directly into liquid
nitrogen, and frozen cell pellets were stored at 270°C or thawed immediately.
Cells were thawed in a room temperature water bath, and ammonium sulfate was
added to a final concentration of 0.1 M. The tube was inverted once and
incubated on ice for 30 min. Cells were lysed at 37°C for 2.5 min and centrifuged
at 40,000 3 g for 1 h at 4°C. Soluble protein was collected, dialyzed against 200
volumes of buffer A (150 mM KCl, 20 mM imidazole [pH 7.0], 20 mM b-mer-
captoethanol), and loaded onto a 20-cm3 DEAE-Sephacel column (Pharmacia
Biotech, Piscataway, N.J.) equilibrated in buffer A. The flowthrough fraction was
collected, dialyzed against 200 volumes of buffer B (50 mM NaCl, 20 mM
HEPES [pH 7.5], 20 mM b-mercaptoethanol, 10% glycerol, 0.05% Triton
X-100), and applied to a P-11 phosphocellulose column (1.5 cm3; Whatman),
equilibrated in buffer B. The column was developed with a 22-ml linear gradient
from 0.05 to 1.0 M NaCl in buffer B. Fractions containing the Runt domain were
pooled and exchanged into buffer C (8 mM sodium phosphate [pH 7.5], 50 mM
NaCl, 0.05% Triton X-100, 10% glycerol, 10 mM b-mercaptoethanol), and
loaded onto a hydroxylapatite column (1 cm3; HTP, Bio-Rad Laboratories,
Richmond, Calif.). The hydroxylapatite column was developed with a 40-ml
linear gradient from 8 to 200 mM sodium phosphate in buffer C, and fractions
containing the Runt domain were pooled and stored at 270°C. The Runt domain
concentration was determined by A280 with the molar extinction coefficient ε 5
11,000 M21 z cm21 reported previously (12).
Determination of the active Runt domain concentration. The active Runt
domain concentration was determined by titration of known concentrations of
DNA onto a fixed concentration of the Runt domain, as described previously
(12). The DNA site used in the titrations was derived from the TCRb enhancer
(GGATATATGTGGTTTGCA). Oligonucleotide concentrations were deter-
mined by measuring A260, using extinction coefficients calculated with the Oligo
program (National Biosciences, Inc.). One milliliter of a 1:15 dilution of
[g-32P]ATP (7,000 Ci/mmol; ICN) was used to label 250 pmol of single-stranded
oligonucleotide. A portion of the single-stranded DNA was set aside for quan-
titative purposes (see below), and the remainder of the labeled strand was
annealed to an unlabeled complementary strand. All binding reactions and
electrophoretic mobility shift assays (EMSA) were performed as described pre-
viously (12). Briefly, binding reactions (20 ml of total volume) were performed at
4°C for 20 min in a solution consisting of 10 mM Tris-HCl (pH 7.5), 100 mM
NaCl, 1 mM EDTA, 5 mM dithiothreitol, 0.2 mg of bovine serum albumin per ml,
0.05% Triton X-100, and 4% glycerol. The Runt domain concentration in all
reaction mixtures (5 3 1028 M) was 100-fold above the Kd of the Runt domain
for this particular DNA site, and the concentration of DNA was varied. Portions
(15 ml) of the binding reaction mixtures were loaded onto a running gel (10%
polyacrylamide) at 4°C to separate free DNA from protein-bound DNA. For
each DNA concentration, three reaction mixtures were analyzed: (i) one with the
Runt domain added, (ii) a control containing the double-stranded DNA probe
alone, and (iii) the labeled single-stranded DNA of known concentration. The
amount of free DNA in each lane was determined with a PhosphorImager 445SI
Scanner (Molecular Dynamics, Sunnyvale, Calif.) and IPLab gel. [Df], the con-
centration of free double-stranded DNA in lanes containing the Runt domain,
and [Dt], the concentration of free double-stranded DNA in the corresponding
control lane without added Runt domain, were determined by comparison to the
free single-stranded DNA standard of known concentration. The concentration
of bound DNA, [PD], was determined from the equation [PD]/[Dt] 5 1 2
[Df]/[Dt]. Concentrations of active protein were determined from the asymptote
when [PD] versus [Dt] was plotted.
Equilibrium dissociation constants. Equilibrium dissociation constants were
determined by the method of Jonsen et al. (32), using the binding and EMSA
conditions described above. DNA concentrations were at least 10-fold lower than
the estimated Kd of the Runt domain for the DNA site, ensuring the total active
protein concentration, [Pt], was an accurate estimate of free protein, [P]. The
fraction of free DNA, [Df]/[Dt], was the ratio of the free DNA signal analyzed at
each protein concentration to the DNA signal in a control lane containing no
protein. The fraction of DNA in complex with protein was derived from the
equation [PD]/[Df] 5 1 2 [Df]/[Dt]. All datum points were fit to the rearranged
mass action equation, [PD]/[Dt] 5 1/(1 1 Kd/[P]), using nonlinear least-squares
analyses (Kaleidagraph; Synergy Software).
Sequences of the double-stranded binding sites used to measure the equilib-
rium dissociation constants are listed on the next page.
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Moloney MLV 59-GGATATCTGTGGTAAAGCA-39
39-CCTATAGACACCATTTCGT-59
SL3-3 MLV 59-GGATATCTGTGGTTAAGCA-39
39-CCTATAGACACCAATTCGT-59
Akv 59-GGATATCTGTGGTCAAGCA-39
39-CCTATAGACACCAGTTCGT-59
MCF247 59-GGATATCTGTGGTCGAGCA-39
39-CCTATAGACACCAGCTCGT-59
Rauscher MCF 59-GGATATCTGCGGTGAGCA-39
39-CCTATAGACGCCACTCGT-59
MX 59-GGATATCGGTGGTCAAGCA-39
39-CCTATAGCCACCAGTTCGT-59
Soule MLV 59-GGATATCTGCGGTCAGCA-39
39-CCTATAGACGCCAGTCGT-59
TCRa 59-GGATATATGTGGCTTGCA-39
39-CCTATATACACCGAACGT-59
TCRbd 59-GGATATATGTGGTTTGCA-39
39-CCTATATACACCAAACGT-59
TCRg 59-GGATATCTGTGGTTTGCA-39
39-CCTATAGACACCAAACGT-59
HA 59-GGATATTTGCGGTTAGCA-39
39-CCTATAAACGCCAATCGT-59
SAAB 59-GGATATCTGCGGTTTGCA-39
39-CCTATAGACGCCAAACGT-59
SS4 59-GGATATCTGCGGAAGGCA-39
39-CCTATAGACGCCTTCCGT-59
SS5 59-GGATATCTGTGGAAGAGCA-39
39-CCTATAGACACCTTCTCGT-59
Mo(core) 59-GGATATCTGCCGTAAAGCA-39
59-CCTATAGACGGCATTTCGT-59
Plasmids and mutations. DNA fragments used for subcloning were derived
from the plasmids pMoCAT, pMo(CORE)CAT, and pMoDRVCAT. pMoCAT
contains the wild-type Moloney MLV enhancer linked to the bacterial chloram-
phenicol acetyltransferase (CAT) gene, and pMo(CORE)CAT is the same plas-
mid with mutations in both core sites of the Moloney MLV enhancer that reduce
CBFa2 binding by 1,000 fold (71; this study). pMoDRVCAT lacks the EcoRV-
EcoRV fragment within the enhancer direct repeat. From these initial plasmids,
four additional vectors were made: pMoRV (Fig. 1) contains the EcoRV-EcoRV
enhancer fragment from pMoCAT, subcloned into the EcoRV site of pBlue-
script SK1 (Stratagene). pMoLUC, pMoDRVLUC, and pMo(CORE)LUC con-
tain a Sau3AI-KpnI fragment from the Moloney MLV U3/R region subcloned
into the BamHI-KpnI site of the pxp1 vector, a promoterless vector containing
the firefly luciferase gene (LUC) (14, 49).
The strategy for introducing core site mutations into the Moloney enhancer is
illustrated schematically in Fig. 1. Mutations were made by PCR, using primers
with the following sequences (core sites are underlined, and lowercase letters
indicate the mutated nucleotides), in conjunction with an antisense primer
(LUC) from luciferase coding sequences: Soule (sense), 59-CAGGATATCTGc
GGTcAGCAGTTCC-39; SL3-3 (sense), 59-CAGGATATCTGTGGTtAGCAG
TTCCT-39; MX (sense), 59-CAGGATATCgGTGGTcAGCAGTTCC-39; SS4
(sense), 59-CAGGATATCTGcGGaAgGCAGTTCCTG-39; SS5 (sense), 59-CA
GGATATCTGTGGaAgGCAGTTCCTG-39; and LUC (antisense), 59-CCGGG
CCTTTCTTTATGT-39.
All core site sequences were terminated at the 59 and 39 ends of the CBF
phosphate contacts defined previously (underlined) (43). Core sequences were
fused directly to Moloney MLV flanking sequences in such a way as to maintain
the orientation and spacing of other protein binding sites on the Moloney
enhancer. Mutations were introduced into each copy of the direct repeat in two
separate subcloning steps. First, each sense primer was used with the LUC1
antisense primer and pMoDRVLUC as a template in PCRs that amplified from
nucleotide 8029 of the Moloney MLV genome to nucleotide 86 of the luciferase
gene. The PCR products were digested with EcoRV and KpnI, and isolated
fragments were used to replace the corresponding region in pMoDRVCAT to
create the pMo(*)DRVCAT vectors [pMo(Soule)DRVCAT, pMo(SL3)DRV-
CAT, pMo(MX)DRVCAT, pMo(SS4)DRVCAT, and pMo(SS5)DRVCAT] (Fig.
1A). Core site mutations were independently introduced into the 75-bp EcoRV-
EcoRV fragment of the Moloney enhancer by PCR using pMoRV as a template
and the same sense primers in conjunction with an antisense primer that hybrid-
izes to the T7 promoter in the pBluescript SK1 vector. The PCR products were
digested with EcoRV and subcloned into the EcoRV site of the pMo(*)DRVCAT
vectors, generating pMo(*)CAT vectors with identical core site mutations in
both copies of the Moloney MLV enhancer direct repeat [pMo(Soule)CAT,
pMo(SL3)CAT, pMo(MX)CAT, pMo(SS4)CAT, and pMo(SS5)CAT] (Fig. 1B).
Finally, these mutated Moloney enhancers were excised from the pMo(*)CAT
plasmids with Sau3A1 and KpnI and transferred into the BamHI-KpnI sites of
the firefly luciferase vector (pxp1) to generate pMo(Soule)LUC, pMo(SL3)LUC,
pMo(MX)LUC, pMo(SS4)LUC, and pMo(SS5)LUC (Fig. 1C). The correct se-
quence of all enhancer segments generated by PCR was confirmed.
Substitution of the mutated Moloney MLV enhancers into the infectious
Moloney MLV genome was performed as described previously (70).
Cell lines. Cell lines were used in transfection experiments or for the gener-
ation of infectious virus as follows. A human mature T-cell line (Jurkat) and a
murine pro-T-cell line (2017) were maintained in RPMI 1640 supplemented with
10% fetal bovine serum (FBS), 100 U of penicillin per ml, 100 mg of streptomycin
per ml, and 2 mM L-glutamine. A murine mature T-cell line, D5H3, was main-
tained in Dulbecco modified Eagle medium supplemented with 10% FBS, 100 U
of penicillin per ml, 100 mg of streptomycin per ml, 2 mM L-glutamine, 0.01 M
HEPES (pH 7.9), and 5 mM b-mercaptoethanol. After transfection, D5H3 cells
were transferred into the same medium with 5% FBS and 5% newborn bovine
serum. NIH 3T3 cells were maintained in Dulbecco modified Eagle medium with
10% FBS, 2 mM L-glutamine, and antibiotics.
Luciferase assays. Cells were transfected by the DEAE-dextran method (34).
Briefly, 107 Jurkat and 2017 cells or 5 3 106 D5H3 cells were transfected with 5
mg of the Mo(*)LUC reporter plasmids and 5 mg of CMVhGH, a plasmid
containing cDNA encoding the human growth hormone driven from a cytomeg-
alovirus enhancer (Nichols Institute Diagnostics, San Juan Capistrano, Calif.).
Jurkat cells were induced with 1 mg of 1,3-phorbol myristate acetate per ml at
24 h posttransfection. Cells were harvested 48 h posttransfection, washed once
with phosphate-buffered saline, and lysed in 160 ml of lysis buffer (1% [vol/vol]
Triton X-100, 25 mM glycylglycine [pH 7.8], 15 mM MgSO4, 4 mM EGTA, 1 mM
dithiothreitol) by vortexing for 30 s at room temperature. Supernatants were
harvested and assayed immediately for luciferase enzyme activity (14, 25). The
results were normalized against protein concentration and human growth hor-
mone levels.
Generating infectious viruses. We transfected three independent molecular
clones of each mutated viral genome into NIH 3T3 cells as previously described
(70). Cells were split 1:10 into duplicate plates 8 to 12 h following transfection,
and XC plaque assays were performed directly on one such plate (63). In all
cases, XC plaques were present. The remaining plate was maintained for 2
weeks, at which time the culture supernatants were assayed for reverse transcrip-
tase activity (4). Virus was harvested after 2 to 3 weeks, by which time the virus
had spread throughout the culture, as determined by XC plaque assay.
Mice, tumor induction, and classification of disease. Newborn (,2-day-old)
NFS mice were inoculated intraperitoneally and intrathymically with 0.04 ml of
tissue culture-grown virus, representing from 104.3 to 105.3 PFU/mouse. Viruses
from two or three independent molecular clones from each enhancer mutation
were injected. Animals were monitored regularly for overt signs of disease.
Diagnosis of erythroleukemia, lymphoma, or myelogenous leukemia was based
on gross pathology and histology, as described previously (10). Briefly, diagnosis
of lymphoblastic lymphoma was based on gross findings of enlarged thymus,
lymph nodes, or both, and histological observation of diffuse infiltration with
lymphoblasts of splenic white pulp, thymus, and lymph nodes, and often liver.
Spleens were normally but not invariably enlarged. Spleen DNA from cases of
lymphoblastic leukemia without thymic enlargement was analyzed for TCRb and
immunoglobulin heavy-chain (IgH) rearrangements by Southern blotting (26, 29,
35). Mice with erythroleukemia showed severe anemia and had enlarged spleens
with erythroblast infiltration of expanded red pulp and enlarged livers with blast
infiltration within sinusoids, the thymus was never enlarged, and lymph nodes
were normal or showed enlarged germinal centers.
RESULTS
Expression and purification of the Runt domain. We used
the isolated DNA-binding Runt domain from the murine
CBFa2 protein to measure equilibrium dissociation constants
for different core sites. Although the Runt domain’s affinity for
any given DNA site may differ from that of the full-length
CBFa2-CBFb heterodimer, its relative affinities for different
core sites should be comparable to those of the full-length
proteins. We expressed a fragment spanning amino acids 41 to
190 of CBFa2 that contains the Runt domain, plus additional
sequences at the N and C termini of the Runt homology region
that we found improved both expression in bacteria and DNA
binding (unpublished results). We also added the pentapeptide
KNQHE to the C terminus of the Runt domain that was shown
to decrease degradation of the P22 Arc repressor in bacteria
(7, 45, 57, 58). We purified the Runt domain from the soluble
fraction of a bacterial cell lysate by sequential chromatography
on DEAE-Sephacel, P11 phosphocellulose, and hydroxylapa-
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FIG. 1. Strategy for introducing altered core sites into the Moloney MLV enhancer. (A) Introducing point mutations into the promoter-distal copy of the enhancer
direct repeats. White bars represent sequences from the Moloney MLV genome. Black bars represent sequences from the bacterial chloramphenicol acetyltransferase
(CAT) gene or the luciferase gene (LUC). Black lines represent bacterial vector DNA sequences. A small gray square represents one copy of the 75-bp direct repeat.
The PCR primer locations (arrows) and core site mutations (asterisks) are indicated. The luciferase reporter plasmid (pxp1) is a promoterless vector linked to the firefly
luciferase gene (LUC) (14, 49). Abbreviations: B, BamHI; RV, EcoRV; K, KpnI; S, Sau3AI. (B) Introducing mutations into the promoter-proximal copy of the direct
repeat. (C) Introducing mutated enhancers into the luciferase reporter vector. Sequences from Sau3AI7910-KpnI8296 of Moloney MLV (85) encompass the 75-bp repeat
and extend 30 bp 39 to the viral cap site.
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tite, as described in Materials and Methods, and summarized
in Fig. 2 and Table 1. The overall yield of the protein was 20%,
and the estimated purity was .95%.
We determined the concentration of Runt domain active for
DNA binding by titrating DNA of known concentration onto
protein of unknown active concentration until saturation of
protein with DNA was achieved (Fig. 2C). The percent active
protein was approximated from the asymptote of the curve that
resulted from plotting the total concentration of DNA versus
the concentration of protein-DNA complex. The purified Runt
domain was estimated to be 80 to 100% active compared to the
total protein concentration.
Equilibrium dissociation constants of the Runt domain for
various core sites. We measured the affinity of the Runt do-
FIG. 2. Expression and purification of the CBFa2 Runt domain. (A) Schematic diagram of full-length CBFa2(451) (3) with the boundaries of the expressed Runt
domain shown below. Black rectangles indicate the 128-amino-acid region of homology shared by the Drosophila and mammalian CBFa proteins. The t(8;21)(q22;q22),
t(3;21)(q26;q22), t(16;21)(q24;q22), and t(12;21)(p13;q22) breakpoint locations are indicated by arrows. The KNQHE C-terminal tag is indicated by the gray bar. (B)
Purification of the CBFa2 Runt domain. (Left) Coomassie brilliant blue-stained sodium dodecyl sulfate-polyacrylamide gel with active fractions from each step of the
purification. Lanes: M, molecular markers (in kilodaltons); 1, soluble supernatant from crude bacterial cell lysate; 2, DEAE-Sephacel flowthrough fraction; 3,
phosphocellulose eluate; 4, hydroxylapatite eluate. The arrow indicates the location of the CBFa2 Runt domain fragment. (Right) Silver-stained sodium dodecyl
sulfate-polyacrylamide gel of representative active fractions (66 to 94) from the hydroxylapatite column. Lane L (for load) contains the phosphocellulose eluate. (C)
Activity of the purified Runt domain quantified by DNA titration in an EMSA. Concentrations (molar) of protein-DNA complex [PD] versus total input DNA [Dt] are
plotted.
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main for different core sites (Table 2) by equilibrium binding
analysis, using the EMSA. The core sites tested were derived
from MLV enhancers (23, 73), the TCRa, -b, -g, and -d en-
hancers (21, 30, 59, 60), and five synthetic sites. The five syn-
thetic sites include the high-affinity (HA) site identified by
Thornell et al. (77), a site identified by selected and amplified
binding analysis (SAAB) (43), a site containing an A at posi-
tion 7 known to decrease CBF binding (SS4) (33), a site similar
to SS4 that incorporates a C3T transition at the fourth posi-
tion (SS5), and the original mutant core site, Mo(core), that
altered disease specificity of Moloney MLV from T-cell leuke-
mia to erythroleukemia (70). All core sites were flanked at the
59 and 39 ends with sequences derived from the Moloney MLV
enhancer. Affinities of the CBFa2 Runt domain for different
core sites were determined by titrating purified Runt domain
of known active concentration onto DNA at a concentration at
least 10-fold lower than the Kd of the Runt domain for that
site. The Runt domain-DNA complex was separated from free
DNA by EMSA, and the ratio of Runt domain (CBFa)-DNA
complex to total DNA (Dt) was then plotted against the active
concentration of the Runt domain to obtain a Kd value (Fig. 3
and Table 3).
The equilibrium dissociation constants of the CBFa2 Runt
domain for the core sites tested spanned 5 orders of magni-
tude. We organized the sites into six groups (Table 3). Group
I contains the highest-affinity sites and includes the site iden-
tified by selected and amplified binding analysis (CTGCGGT
TT) (43), and the original high-affinity site identified by Thor-
nell et al. (TTGCGGTTA) (77). Group I also includes the core
site from the Soule MLV enhancer (CTGCGGTCA). All three
high-affinity sites contain a C in the fourth position (underlined
in each site). Values obtained with the Soule MLV core site
fluctuated from one experiment to the next for unknown rea-
sons. Thus, data from six separate experiments were plotted on
one graph to obtain the best possible Kd estimate for the Soule
site (Fig. 3).
The core sites in the Moloney, SL3-3, and Akv enhancers fell
into the second highest affinity group (Table 3, group II). The
group II sites had, on average, a 10-fold-lower affinity for the
Runt domain than the group I sites. All of the group II sites,
except for the Rauscher MLV site, possess a T in the fourth
position, as opposed to the C found in the highest-affinity
group I sites. The Runt domain affinities for the Moloney and
SL3-3 MLV core sites were equivalent. The Runt domain
affinity for the Akv core site was less than twofold lower than
for the SL3-3 MLV site, consistent with previously published
data (86).
Group III sites include the TCRa and -b core sites, and the
site found in the endogenous polytropic MX33 and MX27
viruses (MX). Both the TCRa and -b sites differ from those in
groups I and II at position 1 (A versus C), a substitution
previously shown by Thornell et al. (77) to decrease CBF
binding. MX is unique among sites with a G at position 2,
which was also previously shown to decrease CBF binding (77).
Group IV consists of the SS4 site, which has the favorable C
TABLE 2. Core sites used for equilibrium binding analysisa
Virus, enhancer, or siteb Core sitesequence
Consensus sequence ...............................................................................................................................................................................................NYGYGGTNN
Moloney MLV, Friend MLV, Moloney MSV, 4070-a, HaMSV, MPSV, Cas-Br-E, NS6MCF, and ABLV ..............................................CTGTGGTAA
SL3-3, GrLV, FeLV-B, FeLV-A, and HoLV .....................................................................................................................................................CTGTGGTTA
Akv, GAL-SE, GAL-SF, SSV, Ki-MSV, RadLV, N-CL-35, B-CL-11, BL/Ka, FBJ-MSV, RFV-en, and AKR614 ..................................CTGTGGTCA
MCF247, MCF13, Tikaut, NZB-x, and NSF-x ...................................................................................................................................................CTGTGGTCG
Rauscher MCF and Rauscher SFFV ...................................................................................................................................................................CTGCGGTGA
MX33 and MX27....................................................................................................................................................................................................CGGTGGTCA
Soule MLV...............................................................................................................................................................................................................CTGCGGTCA
TCRa........................................................................................................................................................................................................................ATGTGGCTT
TCRg and TCRd ....................................................................................................................................................................................................CTGTGGTTT
TCRb........................................................................................................................................................................................................................ATGTGGTTT
HA.............................................................................................................................................................................................................................TTGCGGTTT
SAAB ........................................................................................................................................................................................................................CTGCGGTTT
SS4............................................................................................................................................................................................................................CTGCGGAAG
SS5............................................................................................................................................................................................................................CTGTGGAAG
Mo(core) ..................................................................................................................................................................................................................CTGCCGAAA
a Core site sequences from enhancers of MLVs (23, 73), TCRa, -b, -d, and -g enhancers (21, 30, 59, 60), and five synthetic sites, i.e., the high-affinity (HA) site
identified by Thornell et al. (77), the site identified by selected and amplified binding analysis (SAAB) (43), the SS4 and SS5 sites, and the Moloney core site mutation
Mo(core) originally made by Speck et al. (70, 71). The consensus sequence identified by Melnikova et al. (43) is indicated at the top. The boundaries of the core sites
are defined by the phosphate contacts made by CBF in the Moloney MLV enhancer (43).
b The sites in boldface type represent the names chosen for each site used in the equilibrium binding analysis. Abbreviations: Moloney MSV, Moloney murine
sarcoma virus; HaMSV, Harvey MSV; ABLV, Abelson leukemia virus; GrLV, Gross passage A leukemia virus; FeLV-B and FeLV-A, feline leukemia virus, B and A
subgroup, respectively; HoLV, Ho wild mouse leukemia virus; GAL-SE and GAL-SF, Gibbon ape leukemia virus, SEATO and San Francisco isolates; SSV, simian
sarcoma virus; Ki-MSV, Kirsten MSV; RadLV, radiation-induced leukemia virus; FBJ-MSV, Finkel, Biskis, Jinkins murine osteogenic sarcoma virus; RFV-en,
chemically induced endogenous retrovirus from RFM-Un mice; NZB-x, NZB xenotropic MLV; NSF-x, NFS-Th-1 xenotropic leukemia virus; Rauscher SFFV, Rauscher
spleen focus-forming virus; MX33 and MX27, endogenous polytropic viruses.
TABLE 1. Purification of the CBFa2 Runt domaina
Amt (mg) of:
Fold
purification
Total
yield (%)Total proteinb Runtdomainc
92.5 5.65 100
12.3 1.86 2.46 33
2.80 1.69 9.87 30
1.11 1.11 16.37 20
a Data are for a single preparation starting with a 4-liter bacterial culture.
b Protein was measured by Bio-Rad DC protein assay with bovine serum
albumin as a standard.
c Runt domain was quantified by Coomassie brilliant blue staining of a sodium
dodecyl sulfate-polyacrylamide gel.
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shared by the highest-affinity core sites in group I (CTGCGG
AAG), but an A at position 7 where T is found in most other
sites (CTGCGGAAG). We created an even lower affinity site
by replacing the C in the fourth position of SS4 with a T to
generate SS5 (CTGTGGAAG). Group V consists of the SS5
site. The lowest-affinity site, Mo(core), was the sequence orig-
inally introduced into the Moloney MLV enhancer by Speck et
al. (70), which significantly altered the disease specificity of
FIG. 3. Equilibrium dissociation constants (Kd) for the CBFa2 Runt domain on representative core sites. EMSAs were performed in the presence of increasing
concentrations of the Runt domain indicated on the x axis, plotted against the percent Runt domain (CBFa)-DNA complex formation on the y axis. For each core site,
data from at least two experiments are presented as points plotted on a single graph and fit to a single curve to obtain the Kd.
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Moloney MLV from T-cell leukemia to erythroleukemia. The
2-bp mutation in this site (CTGCCGAAG) presumably dis-
rupts contacts made by CBF to the purine base in the fifth
position (82). Weak binding precluded measurement of an
accurate Kd value for this core site, and therefore only an
approximate Kd is reported. Group VI consists of the Mo(core)
site.
The Kd values obtained for the HA and SL3 sites are lower
than those reported elsewhere from our laboratory (12, 13).
We believe this is due to the presence of the C-terminal
KNQHE tag in this particular Runt domain fragment, which
may somehow stabilize the overall fold of the isolated domain.
Relationship of CBF affinity and transcriptional activity. To
determine whether there is a correlation between the affinity of
CBF for different core sites and transcriptional activity in T
cells, core sites with a range of affinities for the Runt domain
were engineered into the Moloney MLV enhancer, and tran-
scriptional activity was measured in several T-cell lines. One
core site from each of groups I to VI was analyzed. Sites were
chosen to reduce the possibility of interfering with protein
assembly on adjacent sites in the Moloney MLV enhancer. For
example, the Soule MLV site (CTGCGGTCA) was chosen to
represent group I, since the HA site (TTGCGTTA) has a
substitution at position 1 relative to Moloney MLV (CTGTG
GTAA) that could theoretically perturb proteins binding to
sequences immediately flanking the core site. The Soule MLV
site was also deemed preferable to the selected and amplified
binding site (SAAB) because it shares an A with Moloney
MLV at position 9. The core sites engineered into the Moloney
MLV enhancer in order of affinity from highest to lowest are as
follows: Soule . SL3-3 . MX . SS4 . SS5 . Mo(core). PCR
mutagenesis was used to introduce the selected core sites into
both copies of the Moloney MLV direct repeat, which in turn
was subcloned into a reporter plasmid containing the firefly
luciferase gene (see Material and Methods and Fig. 1). Tran-
scription was analyzed in three T-cell lines; Jurkat, 2017, and
D5H3 (Fig. 4). The pattern of transcriptional activity from cell
line to cell line was very similar. In general, Moloney MLV
enhancers containing the higher-affinity sites (groups I and II)
displayed a higher level of transcriptional activity than Molo-
ney MLV enhancers with lower-affinity sites (groups III and
VI), but a strict correlation between core site affinity and tran-
scriptional activity was not observed. Specifically, there was not
a linear decrease in transcriptional activity that matched the
progressive decrease in core site affinity for CBF. For example,
the enhancer with the highest-affinity core site (Soule MLV, Kd
5 5.7 3 10212 M), displayed only half the transcriptional
activity in all three T-cell lines compared to the enhancer
containing the next lowest affinity core site, SL3-3 (Kd 5 2.4 3
10211 M). An even more dramatic deviation was observed with
the MX core site (Kd 5 1.7 3 10
210 M) from group III, which
conferred almost no transcriptional activity in any T-cell line
tested. The level of transcription driven by the MX core site
was equal to or below that conferred by the lowest-affinity site,
Mo(core), despite the fact that the Runt domain affinity for the
MX site was approximately 200-fold higher than for Mo(core)
(Kd $ 4.0 3 10
28 M).
Pathogenesis of Moloney MLVs containing altered core
sites. We introduced core sites from groups I to VI into the
Moloney MLV genome, generated infectious viruses, and an-
alyzed the pathogenicity of these viruses in newborn NFS mice.
Virus stocks generated from two or three independent molec-
ular clones for each enhancer mutation were analyzed (Fig. 5
and Table 4). All viruses were leukemogenic, but their patho-
genic properties varied. The latent period of disease onset
appeared to inversely correlate with the transcriptional activity
conferred by these core sites in T cells. The viruses could be
divided into two groups with respect to latent period (Fig. 5).
Viruses containing high-affinity core sites (Mo:Soule and Mo:
SL3-3) that conferred relatively high transcriptional activity in
T cells induced disease with significantly shorter latent periods
than viruses containing low-affinity sites (Mo:MX, Mo:SS4,
Mo:SS5, and Mo:core). The differences in latent periods
among the three high-affinity core site viruses (Moloney, Mo:
Soule, and Mo:SL3-3) or among the viruses containing low-
affinity sites (Mo:MX, Mo:SS4, Mo:SS5, and Mo:core) were
not statistically significant by analysis of variance. By this anal-
ysis, however, there was a statistically significant difference
between the latent periods of disease onset associated with the
higher-affinity core site viruses (Moloney, Mo:Soule, and Mo:
SL3-3) and the latencies associated with the lower-affinity core
site viruses (Mo:MX, Mo:SS4, Mo:SS5, and Mo:core).
Table 4 shows the frequency of each type of hematopoietic
neoplasm induced by viruses containing mutations in the en-
hancer sequence. Moloney viruses containing cores sites from
groups I and II (including wild-type Moloney MLV) induced
exclusively T-cell lymphomas. Moloney viruses containing the
lower-affinity MX core site (group III) induced primarily lym-
phoblastic lymphomas (12 of 17 neoplasms [71%]). In three
additional cases, splenomegaly and lymphadenopathy were
predominant features but molecular analysis of the TCRb and
IgH loci detected no rearrangements. Histologically these tu-
mors were poorly differentiated, composed of lymphoblast-like
cells with abundant cytoplasm, vesicular chromatin pattern,
and prominent nucleoli, with undifferentiated, possibly my-
eloid blasts in peripheral smears. These cases could represent
very early B-cell lymphomas that have not rearranged their
IgH alleles, as may be the case in prenatal pre-B-cell lympho-
mas in Em-myc and Em-pim-1 double transgenic mice (79), or
they could be lymphomas of lymphoid precursors or stem cells.
Further testing will be required to classify these cases defini-
tively.
The Mo:SS4 virus induced two cases of myelogenous leuke-
mia and two of lymphoblastic leukemia (T- or B-cell origin not
molecularly determined). The small numbers of mice infected
with Mo:SS4 precludes a clear definition of its pathogenicity.
Viruses in the groups with the lowest-affinity sites groups V
and VI (Mo:SS5 and Mo:core) induce no myeloid tumors, but
TABLE 3. Summary of equilibrium binding constants
Group Core site Sequence Kd (M)
I HA TTGCGGTTA 2.7 3 10212
SAAB CTGCGGTTT 5.5 3 10212
Soule MLV CTGCGGTCA 3.5 3 10212
II Moloney MLV CTGTGGTAA 2.9 3 10211
SL3-3 MLV CTGTGGTTA 2.4 3 10211
Akv CTGTGGTCA 3.5 3 10211
MCF247 CTGTGGTCG 4.9 3 10211
Rauscher MCF CTGCGGTGA 2.7 3 10211
TCRg CTGTGGTTT 3.9 3 10211
III TCRa ATGTGGCTT 1.4 3 10210
MX CGGTGGTCA 1.7 3 10210
TCRb ATGTGGTTT 8.3 3 10211
IV SS4 CTGCGGAAG 9.0 3 10210
V SS5 CTGTGGAAG 6.1 3 1029
VI Mo(core) CTGCCGTAA $4.0 3 1028
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a significant percentage of erythroleukemias. Therefore, T-cell
disease specificity appeared to correlate with core site affinity,
in that viruses with relatively low-affinity core sites do not
maintain the exquisite T-cell disease specificity of Moloney
MLV and instead induce a variety of leukemias.
DISCUSSION
CBF is one of many proteins that bind MLV enhancers and
one of several transcription factors that bind the core site.
Here we show that the affinity of CBF for its DNA-binding site
in Moloney MLV correlates with the latent period of disease
onset and disease specificity of the virus. Altered Moloney
viruses that contain high-affinity CBF binding sites induce pre-
dominantly thymic lymphoblastic lymphomas, whereas viruses
with lower-affinity CBF binding sites lose the exquisite T-cell
disease specificity of Moloney MLV. The results suggest that
CBF, which was identified as a candidate host cell transcription
factor responsible for the T-cell disease specificity of Moloney
MLV (82), may in fact be contributing to the T-cell disease
specificity of this virus in vivo. It is also formally possible that
we inadvertently created high-affinity binding sites for proteins
expressed in hematopoietic cells other than T cells upon in-
troducing low-affinity CBF binding sites into the Moloney
MLV enhancer and that this caused alterations in disease
specificity.
Although the affinity of CBF for its site appears to correlate
with the latent period of disease onset and T-cell disease spec-
ificity, it does not do so in a linear fashion. Rather, there
appears to be an affinity threshold for inducing T-cell lym-
phoma following a rapid latent period. The Moloney, Mo:
Soule, and Mo:SL3-3 MLVs contain core sites above this af-
finity threshold and induce exclusively T-cell lymphomas
following a short latent period. Mo:MX, Mo:SS4, Mo:SS5, and
Mo:core contain core sites below the affinity threshold and
induce a mixture of T- and B-cell lymphomas, myeloid leuke-
mias, and erythroleukemias following a longer latent period.
Although there was a rough correlation between CBF affin-
ity and transcriptional activity in T cells, two core sites deviated
from this pattern for reasons we do not fully understand. The
Soule MLV core site, which is in the group of high-affinity sites
(group I), and bound CBF with a sevenfold-higher affinity than
the SL3-3 core site, conferred lower levels of transcription to
the Moloney MLV enhancer than the SL3-3 site. The difficulty
we experienced in measuring a dissociation constant for the
Soule MLV site may have caused us to underestimate the Kd,
although in no experiments did we measure a Kd for the Soule
core site that was higher than that for SL3-3. Another possible
explanation for this discrepancy is that the mutation we intro-
duced in the Moloney enhancer to generate the Soule MLV
site may have altered binding of other proteins to the en-
hancer. In this regard, we note that the C at position 8 of the
Soule site is shared by the Akv virus. In other studies, it has
been demonstrated that the C at position 8 in Akv, when used
FIG. 4. Effects of different core sites on transcription driven by the Moloney MLV enhancer in T cells. (A) Sequence represents the promoter-distal copy of the
direct repeat (dr). Core mutations were introduced into both copies of the direct repeat. Binding sites for nuclear factors are boxed. Bases identical to those in the
Moloney MLV enhancer are indicated by dots, and capital letters indicate base pair substitutions. (B) Transcriptional activity in Jurkat cells, induced with 1,3-phorbol
myristate acetate (1 mg/ml) 24 h posttransfection, 2017 cells, and D5H3 cells. Core sites are arranged in order of decreasing affinity for the Runt domain (from left to
right). The absolute luciferase activity was normalized to the protein concentration in each sample (relative luciferase units [RLU] on the y axis. Datum points represent
the means of three experiments performed on the same day. Error bars represent the standard deviations for the three experiments.
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to replace the T at that same position in the SL3-3 virus,
reduces transcription from the SL3-3 enhancer in T cells and
attenuates pathogenesis (6, 47). Similarly, this alteration in the
Moloney MLV enhancer, while not significantly affecting CBF
affinity (compare the Moloney MLV and Akv sites in Table 3),
may nevertheless be responsible for reducing transcriptional
activity in T cells. Our experiments support the hypothesis put
forth by Zaiman et al. (86), that the T-versus-C difference in
the SL3-3 and Akv core sites is most likely influencing tran-
scription and pathogenesis through some protein other than
(or in addition to) CBF, since the affinities of CBF for the
SL3-3 and Akv sites are very similar.
The other unexpected result was that obtained with the
endogenous polytropic and modified polytropic MX viruses.
When this core site was introduced into the Moloney MLV
enhancer, it dramatically reduced transcription in T cells, as
much as or even more than the Mo(core) mutation that essen-
tially eliminates CBF binding. Again, the data suggest that the
sequence alteration impacted on some other protein binding to
the enhancer in T cells. The Ets proteins, for example, bind the
adjacent LVb site 59 to the core site. However, preliminary
data (not shown) indicated that Ets-1 binding was not appre-
ciably affected by the MX mutation. The MX site also has a C
at position 7, similar to Soule and Akv. Pathogenicity was
affected, in that there was increased heterogeneity in tumor
phenotype and latency was prolonged.
We note that most MLVs contain relatively high-affinity
CBF binding sites (groups I and II). Only the endogenous
polytropic and modified polytropic viruses (MX27 and MX33)
contain low-affinity CBF sites. The endogenous polytropic vi-
ruses are replication defective and serve as env donors for
recombinant MCF viruses, but the enhancers from these vi-
FIG. 5. Leukemia induction in NFS mice. Leukemia induction as a function of time, following injection of newborn NFS mice with the wild-type Moloney virus and
viruses containing altered core sites.
TABLE 4. Latent period of disease induction and types of leukemia and lymphoma cause by wild-type and mutant Moloney viruses
Virus Core site Kd(M)
No. positive/no.
inoculateda
Avg
latent
period
(days)b
No. of tumors (%)c
Lymphoblastic lymphoma
Myelogenous
leukemia Erythroleukemia OtherT-cell
Lymphoma
B-cell
lymphoma Untyped
d
Moloney 2.9 3 10211 12/12 71 (11) 12 (100) 0 0 0 0 0
Mo:Soule 3.5 3 10212 10/12 76 (12) 10 (100) 0 0 0 0 0
Mo:SL3-3 2.4 3 10211 14/14 64 (12) 13 (100) 0 0 0 0 1e
Mo:MX 1.7 3 10210 17/18 166 (46) 5 (36) 2 (14) 5 (36) 1 (6)e 1 (6) 3f
Mo:SS4 9.0 3 10210 6/9 148 (43) 0 0 2 (50) 2 (50) 0 2e
Mo:SS5 6.1 3 1029 14/20 163 (52) 7 (64) 1 (9) 1 (9) 0 2 (18) 2e
Mo:coreg .4.0 3 1028 19/24 162 (26) 5 (28) 0 0 0 11 (61) 1e, 2h
a Number of mice positive by 9 months postinoculation, at which point the experiment was terminated, to the number of mice inoculated.
b Average latent period is calculated from animals with disease that were sacrificed or found dead. Standard deviations are in parentheses.
c Lineage typing of cases of lymphoblastic lymphoma with no thymic involvement were based on TCRb and IgH rearrangements detected in Southern blots of spleen
or lymph node DNA. The percentage of each lymphoma or leukemia relative to all diagnosed disease is indicated in parentheses.
d Nonthymic lymphoma, not tested for TCRb or IgH rearrangements.
e Dead, no diagnosis.
f Non-thymic, non-T, non-B by TCRb and IgH rearrangement. Morphologically lymphoblastic but poorly differentiated, with undifferentiated blasts in peripheral
smears.
g Data from Speck et al. (70). Molecular analysis of TCRb and IgH rearrangements not performed.
h Lymphoma plus erythroleukemia (11%).
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ruses are not found in infectious MLVs (73). Thus, it appears
that CBF has the potential to act on most MLV enhancers in
vivo.
The expression pattern of Cbfa2, which encodes the CBFa
subunit originally purified from thymus tissue (82), may shed
some light on why the lowest-affinity core sites in the Moloney
MLV enhancer [SS5 and Mo(core)] tend to shift disease spec-
ificity toward erythroleukemia. Cbfa2 is highly expressed in
c-kit1 CD341 fetal liver hematopoietic stem cells and in bone
marrow (11, 15, 50). Expression remains high in the thymus
and in some (if not all) myeloid lineages but appears to be
rapidly downregulated in both the primitive and definitive ery-
throid lineages (11, 50, 65, 68). Thus, CBF may not be impor-
tant for Moloney MLV replication in cells of the erythroid
lineage. Low-affinity core sites may selectively impair transcrip-
tion of the Moloney MLV genome in lymphocytes and in
myeloid lineages, but not in erythroid progenitors, hence shift-
ing the distribution of leukemias toward the erythroid lineage.
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